Serological profile of first SARS-CoV-2 reinfection cases detected within the SIREN study.
View / Open Files
Authors
Atti, A
Ferrari, M
Castillo-Olivares, J
Monk, EJM
Gopal, R
Patel, M
Hoschler, K
Cole, MJ
Semper, A
Hewson, J
Otter, AD
Foulkes, S
Islam, J
Mirfenderesky, M
Jain, S
Murira, J
Favager, C
Nastouli, E
Chand, MA
Brown, CS
Heeney, JL
Brooks, T
Hall, VJ
Hopkins, S
Zambon, M
Publication Date
2022-02Journal Title
J Infect
ISSN
0163-4453
Publisher
Elsevier BV
Language
eng
Type
Other
This Version
VoR
Metadata
Show full item recordCitation
Atti, A., Ferrari, M., Castillo-Olivares, J., Monk, E., Gopal, R., Patel, M., Hoschler, K., et al. (2022). Serological profile of first SARS-CoV-2 reinfection cases detected within the SIREN study.. [Other]. https://doi.org/10.1016/j.jinf.2021.09.019
Abstract
OBJECTIVES: To describe the serological profile of first two SARS-CoV-2 confirmed reinfections in the national healthcare worker cohort study SARS-CoV-2 Immunity and Reinfection Evaluation (SIREN) and potentially identify correlates of protection against reinfection. METHODS: In addition to routine testing within the SIREN study, viral culture, sequencing and phylogenetic analysis were performed. Total antibody testing (Anti-SARS-CoV-2 nucleocapsid and Anti-SARS-CoV-2 spike) were complemented by receptor binding domain indirect ELISA and neutralising antibody assays. RESULTS: The first two SARS-CoV-2 confirmed reinfections had mild symptomatic illness episodes from which infectious virus was recovered at the time of reinfection. The recovered viruses and their sequences were closely related to viruses circulating locally during the time of reinfection and serology was consistent with reinfection. Prior to reinfection, both cases had ELISA and immunoblot detectable anti-N antibodies, but lacked live virus neutralising antibody. Within days following reinfection, neutralising antibodies became detectable and anti-N and anti-S binding antibodies were boosted. CONCLUSIONS: We hypothesise that titres of neutralising antibody can be used as a correlate of protection against reinfection. Further analysis using a case-control design is essential in order to confirm this hypothesis.
Keywords
COVId-19, COVId-19 serological testing, Neutralising antibodies, Reinfection, SARS-CoV-2, Antibodies, Viral, COVID-19, Humans, Immunity, Humoral, Reinfection, SARS-CoV-2
Sponsorship
MRC (via University of Nottingham) (MC_PC_20060)
Identifiers
PMC8482544, 34600935
External DOI: https://doi.org/10.1016/j.jinf.2021.09.019
This record's DOI: https://doi.org/10.17863/CAM.77762
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk